Patents
Literature
Patsnap Copilot is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
35 results about "Weight gain prevention" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
To achieve weight loss or to prevent weight gain during menopause, stay active and eat a healthy diet. If your lifestyle begins to change as you age, try to keep physical activity and portion control at the top of your priority list. When kids move away from home, use your extra time to exercise.
Acylated glucagon analogues
InactiveUS20120178670A1Avoid weight gainGood for weight lossPeptide/protein ingredientsAntipyreticDiabetes mellitusWeight gain prevention
The invention provides materials and methods for promoting weight loss or preventing weight gain, and in the treatment of diabetes and associated metabolic disorders. In particular, the invention provides novel acylated glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
Owner:ZEALAND PHARM AS
Glucagon analogues
InactiveUS20110286982A1Avoid weight gainGood for weight lossOrganic active ingredientsFungiWeight gain preventionProviding material
The invention provides materials and methods for promoting weight loss or preventing weight gain, and in the treatment of diabetes, metablic syndrome and associated disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
Owner:ZEALAND PHARM AS
Glucagon analogues
InactiveUS20110286981A1Avoid weight gainGood for weight lossOrganic active ingredientsFungiWeight gain preventionProviding material
The invention provides materials and methods for promoting weight loss or preventing weight gain, and in the treatment of diabetes, metabolic syndrome and associated disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
Owner:ZEALAND PHARM AS
Glucagon analogues
The invention provides materials and methods for promoting weight loss or preventing weight gain, and in the treatment of diabetes, metablic syndrome and associated disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
Owner:ZEALAND PHARM AS
Glucagon analogues
InactiveUS20130157935A1Effect on cholesterol levelAvoid weight gainPeptide/protein ingredientsMetabolism disorderWeight gain preventionProviding material
The invention provides materials and methods for promoting weight loss or preventing weight gain without affecting glycemic control. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
Owner:ZEALAND PHARM AS
Glucagon analogues
InactiveUS20130316941A1Avoid weight gainGood for weight lossPeptide/protein ingredientsAntipyreticWeight gain preventionGlycemic
The invention provides glucagon analogue peptides and their use for promoting weight loss or preventing weight gain, and the treatment of obesity or excess body weight and associated conditions. The compounds may also be used to improve glycemic control and/or for the treatment of diabetes. The compounds may mediate their effect, inter alia, by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
Owner:BOEHRINGER INGELHEIM INT GMBH +1
Glucagon analogues
The invention provides materials and methods for promoting weight loss or preventing weight gain, and in the treatment of diabetes, metabolic syndrome and associated disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
Owner:ZEALAND PHARM AS
Glucagon analogues
The invention provides materials and methods for promoting weight loss or preventing weight gain, and in the treatment of diabetes, metabolic syndrome and associated disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
Owner:ZEALAND PHARM AS
Glucagon analogues
The invention provides materials and methods for promoting weight loss or preventing weight gain, and in the treatment of diabetes, metablic syndrome and associated disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
Owner:ZEALAND PHARM AS
Acylated glucagon analogues
InactiveUS9156901B2High potencyHigh selectivityPeptide/protein ingredientsAntipyreticDiabetes mellitusWeight gain prevention
The invention provides materials and methods for promoting weight loss or preventing weight gain, and in the treatment of diabetes and associated metabolic disorders. In particular, the invention provides novel acylated glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
Owner:ZEALAND PHARM AS
Methods of preventing weight gain
ActiveUS20060073217A1Prevent and reduce weight gainImprove efficiencyBiocideMetabolism disorderHalf-lifeAgonist
Methods for preventing or reducing weight gain due to factors such as drug use, cessation of smoking, and the like in a human subject, utilizing H1-receptor agonists that have a pharmacological half-life that allows an efficient treatment regime thereof are disclosed.
Owner:OTOLANUM
Glucagon analogues
InactiveUS9403894B2Effect on cholesterol levelAvoid weight gainPeptide/protein ingredientsMetabolism disorderProviding materialWeight gain prevention
The invention provides materials and methods for promoting weight loss or preventing weight gain without affecting glycemic control. In particular, the invention provides novel glucagon analog peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the glucagon-like peptide-1 (GLP-1) receptor as compared to human glucagon.
Owner:ZEALAND PHARM AS
Compositions and methods for managing weight
ActiveUS20140004215A1Promoting and managing weight lossMaintain weightBiocideNervous disorderPsychotropic AgentStimulant
The present disclosure provides Diels-Alder adducts of chalcone and prenylphenyl moieties capable of modulating the activity of cannabinoid receptors, and to oligomers of flavan-3-ol capable of modulating fat absorption and storage. Such Diels-Alder adducts of chalcone and prenylphenyl moieties or oligomers of flavan-3-ol can optionally be used in combination with other weight management agents, such as anorectic agents, a lipase inhibitors, other cannabinoid receptor modulators, psychotropic agents, insulin sensitizers, stimulants, or satiety agents, as well as to methods of use thereof such as treating or preventing weight gain or obesity, promoting weight loss, appetite suppression, modifying satiety, or the like.
Owner:UNIGEN
Modulators of CB1 Receptors
Compounds of formula (I) suppress the normal signalling activity CB1 receptors, and are thus useful in the treatment of diseases or conditions which are mediated by CB1 receptor signalling activity, such as treatment of obesity and overweight, prevention of weigh gain, treatment of diseases and conditions directly or indirectly associated with obesity and overweight: wherein A1 is hydrogen, —COOH,or tetrazolyl; p and q are independently 0 or 1; A3 is phenyl or cycloalkyl, either of which is optionally substituted with R4 and / or R5; R4 and R5 are independently —R9, —CN, —F, —Cl, —Br, —OR9, —NR7R8, —NR7COR6, —NR7SO2R6, —COR6, —SR9, —SOR9, or —SO2R6; R6 is C1-C4 alkyl, cycloalkyl, —CF3 or —NR7R8; R7 and R8 are independently hydrogen, C1-C4 alkyl or cycloalkyl; R9 is hydrogen, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 alkoxy(C1-C4 alkyl)-, cycloalkyl, or fully or partially fluorinated C1-C4 alkyl; R1 (i) a bond; (ii) a divalent radical of formula —(CH2)aB1(CH2)b wherein a and b are independently O, 1, 2 or 3 provided that a+b is 1, 2 or 3, and B1 is —CO—, —O—, —S—, —SO—, —SO2—, —CH2—, —CHCH3—, —CHOH— or —NR7—; or (iii) a divalent radical selected from —C(R10)(R11)—*, —C(R10)(R11)—O—*, —C(R10)(R11)CH2—*, —C(R10)(R11)CH2—O—*, —CH2C(R10)(R11)—*, —CH2C(R10)(R11)—O—*, —CH2—O—C(R10)(R11)—* and —C(R10)(R11)—O—CH2—*, wherein the bond indicated by an asterisk is attached to the pyrazole ring; Z is as defined in the specification; R10 is hydrogen and R11 is (C1-C3)alkyl or —OH; or R10 and R11 are both (C1-C3)alkyl; or R10 and R11 taken together with the carbon atom to which they are attached form a (C3-C5)cycloalkyl ring.
Owner:7TM PHARM AS
Cb1 receptor modulators
Compounds of formula (I) suppress the normal signalling activity CB1 receptors, and are thus useful in the treatment of diseases or conditions which are mediated by CB1 receptor signalling activity, such as treatment of obesity and overweight, prevention of weigh gain, treatment of diseases and conditions directly or indirectly associated with obesity and overweight:
- wherein
- A1 is hydrogen, —COOH, or tetrazolyl, and A2 is hydrogen, —COOH, or tetrazolyl, provided that one of A1 and A2 is either —COOH or tetrazolyl; p is 0 or 1 and A3 is phenyl or cycloalkyl, either of which is optionally substituted with R4 and/or R5; q is 0 or 1; R3 is hydrogen, C1-C4 alkyl, cycloalkyl, —CF3, or —OR9; R4 and R5 independently —R9, —CN, —F, —Cl, —Br, —OR9, —NR7R8, —NR7COR6, —NR7SO2R6, —COR6, —SR9, —SOR9, or —SO2R6; R6 is C1-C4 alkyl, cycloalkyl, —CF3 or —NR7R8; R7 and R8 are independently hydrogen, C1-C4 alkyl, —CF3, or cycloalkyl; R9 is hydrogen, C1-C4 alkyl, cycloalkyl, fully or partially fluorinated C1-C4 alkyl; R1 is (i) a bond, or (ii) —(CH2)aB1(CH2)b— wherein a and b are independently 0, 1, 2 or 3 provided that a+b is 1, 2 or 3; or (iii) —C(R10)(R11)—*, —C(R10)(R11)—O—*, —C(R10)(R11)CH2—*, —C(R10)(R11)CH2—O—*, —CH2C(R10)(R11)—*, —CH2C(R10)(R11)—O—*, —CH2—O—C(R10)(R11)—* or —C(R10)(R11)—O—CH2—*, wherein the bond indicated by an asterisk is attached to the pyrazole ring; R2 is a divalent radical of formula -Q1-A4-[Q2]w- wherein Q1, A4 Q2 and w are as defined in the specification; and R10 is hydrogen and R11 is (C1-C3)alkyl or —OH; or R10 and R11 are both (C1-C3)alkyl; or R10 and R11 taken together with the carbon atom to which they are attached form a (C3-C5)cycloalkyl ring.
Owner:7TM PHARM AS
Methods of treatment with glp-1 receptor agonists
InactiveUS20130090285A1Control weight gainInduce weight lossConnective tissue peptidesPeptide/protein ingredientsDiabetes mellitusRegimen
The invention provides methods for treating diabetes or obesity, as well as methods for inducing weight loss, preventing weight gain, or controlling weight in a patient in need thereof. The methods comprise administering to the patient at least one effective dose of a GLP-1 receptor agonist, or a regimen of GLP-1 receptor agonist comprising a plurality of substantially evenly spaced doses. The effective dose or regimen does not induce substantial nausea or appetite suppression in the patient.
Owner:PHASEBIO PHARMA INC
Pharmaceutical compositions containing berberine for treatment or prevention of weight gain and obesity associated with anti-psychotic drugs
InactiveUS20110281852A1Reduce weightInhibit weight gainBiocideNervous disorderBerberineNatural product
The compositions and methods disclosed herein are of use for the treatment and prevention of weight gain and obesity. In particular, the compositions and methods include treatment of weight gain and obesity with berberine and / or berberine analogs alone or in combination thereof to cause a reduction in an individual's weight or prevent weight gain or obesity. In certain embodiments, the weight gain and obesity are associated with administration of anti-psychotic drugs. In an alternative embodiment, the compositions and methods provide berberine or berberine analogs alone or for coadministration with an anti-psychotic agent. In an additional embodiment, the compositions and methods further include a natural product. The usefulness of the present invention is that berberine and berberine analogs do not have synergistic effects with other drugs and administration results in few side effects. Such characteristics of berberine or berberine analogs are a great improvement able to support the widespread use of the compositions and methods of the present invention as therapeutics for the treatment and prevention of weight gain and obesity.
Owner:DAVIES GARETH +1
Compositions and methods for managing weight
ActiveUS9844576B2Less weight gainImprove the level ofNervous disorderHydroxy compound active ingredientsPsychotropic AgentStimulant
The present disclosure provides Diels-Alder adducts of chalcone and prenylphenyl moieties capable of modulating the activity of cannabinoid receptors, and to oligomers of flavan-3-ol capable of modulating fat absorption and storage. Such Diels-Alder adducts of chalcone and prenylphenyl moieties or oligomers of flavan-3-ol can optionally be used in combination with other weight management agents, such as anorectic agents, a lipase inhibitors, other cannabinoid receptor modulators, psychotropic agents, insulin sensitizers, stimulants, or satiety agents, as well as to methods of use thereof such as treating or preventing weight gain or obesity, promoting weight loss, appetite suppression, modifying satiety, or the like.
Owner:UNIGEN
Methods and compositions for treating obesity, preventing weight gain, promoting weight loss, promoting slimming, or treating or preventing the development of diabetes
ActiveUS20160000745A1Reduce hungerHigh energyBiocideCarboxylic acid nitrile preparationDiabetes mellitusWeight gain prevention
The present invention relates to compositions and kits including a chemical uncoupler, such as tyrphostin 9 or precursor or a salt thereof, and compositions including a chemical uncoupler, such as tyrphostin 9 in combination with one or more therapeutic agents, for example, L-carnitine, which are useful, for example, in treating obesity, preventing weight gain, promoting weight loss/slimming, and/or treating or preventing the development of diabetes.
Owner:NAN GLOBAL LLC
Methods for treating obesity, insulin resistance and inducing satiety
InactiveUS20090123580A1Reduce cholesterolReduce weightBiocideDough treatmentWeight gain preventionObesity
The present invention provides a method for treating an insulin resistance disorder, treating obesity, reducing the weight and / or preventing weight gain and controlling appetite and / or inducing satiety in a subject by administering to the subject an amount of a stabilized rice bran solubilized fraction effective to treat the subject.
Owner:RICEBRAN TECH
Methods of inducing weight loss, treating obesity and preventing weight gain
ActiveUS20190254331A1Improve predictive performanceMassive lossMetabolism disorderFood ingredient functionsGlycemicGlucose polymers
The present disclosure relates to a method of inducing weight loss and/or preventing weight gain in a subject affected by administering certain diets selected based on the fasting blood glucose and/or the fasting insulin of the subject. The present disclosure further provides personalized dietary instruction, based on the fasting blood glucose and/or the fasting insulin of a subject, with the potential to improve the weight loss and prevent weight regain. The present disclosure further relates to methods for predicting weight loss success and classifying responsiveness of a subject to a certain diet as well as methods for selecting a weight loss or a weight gain diet for a subject based on the fasting blood glucose and/or the fasting insulin of the subject.
Owner:UNIVERSITY OF COPENHAGEN
Compositions comprising hyaluronic acid and dermatan sulphate for the treatment of being overweight and obesity
InactiveUS20150182597A1Increase insulin sensitivityInhibit expressionBiocideOrganic active ingredientsDermatan sulfateWeight gain
The present invention relates to a composition comprising hyaluronic acid and dermatan sulphate for use in the treatment or prevention of overweight, obesity, insulin resistance, type 2 diabetes, fatty liver or dyslipidemia or for use in reducing food intake, inducing the feeling of satiety, reducing appetite, reducing body weight, preventing weight gain, reducing body fat, reducing fat formation, reducing blood cholesterol, maintaining normal blood cholesterol levels, reducing blood triglycerides, maintaining normal blood triglyceride levels or increasing insulin sensitivity. The composition can further contain collagen hydrolysate. The composition can be in the form of a pharmaceutical composition, a food, a functional food, a medical food or a food supplement.
Owner:BIOIBI12RICA
Treatment of obesity
InactiveUS20110138888A1Encouraging weight gainIncrease activity levelOrganic active ingredientsPeptide/protein ingredientsObese subjectsWeight gain prevention
The present disclosure relates to the treatment, e.g. reduction, of body fat mass levels for example in overweight and obese subjects. The present disclosure also relates to weight control in a subject where obesity should be avoided. Disclosed herein are methods of reducing body fat mass e.g reducing obesity or preventing weight gain and agents used in such methods whereby the agents inhibit a sulphur containing amino acid. Also included in the present disclosure include, without being limited to, methods for determining regimes for the treatment of obesity as well as other subject matter.
Owner:ISIS INNOVATION LTD
Lachnospiraceae in the gut microbiota and association with body weight
ActiveUS9962415B2Reduce the ratioGood for weight lossBiocideCosmetic preparationsLactobacillus rhamnosusIntestinal microorganisms
The present invention relates to means and methods for modulating the gut microbiota composition of a subject, preferably a human. In particular, the present invention provides an agent capable of reducing the proportion of Lachnospiraceae in the gut microbiota composition of a subject which agent is useful for promoting weight loss or preventing weight gain in a subject, preferably an obese or overweight subject. Lactobacillus rhamnosus CGMCC 1.3724 is particularly preferred as the agent provided by and used in the present invention.
Owner:SOC DES PROD NESTLE SA
Modulators of cb1 receptors
Compounds of formula (I) suppress the normal signalling activity CB1 receptors, and are thus useful in the treatment of diseases or conditions which are mediated by CB1 receptor signalling activity, such as treatment of obesity and overweight, prevention of weigh gain, treatment of diseases and conditions directly or indirectly associated with obesity and overweight: wherein A1 is hydrogen, -COOH, or tetrazolyl, and A2 is hydrogen, -COOH, or tetrazolyl, provided that one of A1 and A2 is either -COOH or tetrazolyl; p is O or 1 and A3 is phenyl or cycloalkyl, either of which is optionally substituted with R4 and / or R5; q is O or 1; R3 is hydrogen, C1-C4 alkyl, cycloalkyi, -CF3, or -OR9; R4 and R5 independently -R9, -CN, -F, -Cl, -Br, -OR9, - NR7R8, -NR7COR6, -NR7SO2R6, -COR6, -SR9, -SOR9, or -SO2R6; R6 is C1-C4 alkyl, cycloalkyl, -CF3 or -NR7R8; R7 and R8 are independently hydrogen, C1-C4 alkyl, -CF3, or cycloaikyL R9 is hydrogen, C1-C4 alkyl, cycloalkyl, fully or partially fluorinated C1-C4 alkyl; R1 is (i) a bond, or (ii) -(CH2)aB1(CH2)b- wherein a and b are independently O, 1, 2 or 3 provided that a+b is 1, 2 or 3; or (iii) -C(R10)(R11)-*, -C(R10)(R11)-O-*. -C(R10)(R11)CH2-*, -C(R10)(R11)CH2-O-*, - CH2C(R10)(R11)-*, -CH2C(R10)(R11)-O-*, -CH2-O-C(R10)(R11)-* or -C(R10)(R11)-O-CH2-*, wherein the bond indicated by an asterisk is attached to the pyrazole ring; R2 is a divalent radical of formula -Q1A4-[Q2]w- wherein Q1, A4, Q2 and w are as defined in the specification; and R10 is hydrogen and R11 is (C1-C3)alkyl or -OH; or R10 and R11 are both (C1-C3)alkyl; or R10 and R11 taken together with the carbon atom to which they are attached form a (C3- C5)cycloalkyl ring.
Owner:7TM PHARM AS
Indoxyl sulfate as a biomarker of prebiotic efficacy for weight gain prevention
InactiveUS20160033473A1Lower Level RequirementsEfficient administrationOrganic active ingredientsBiocideNutritionWeight gain prevention
The present invention relates generally to the field of nutrition and health. In particular, the present invention relates to indoxyl sulfate as a biomarker in urine of the efficacy of prebiotics for the prevention of diet induced weight gain.
Owner:SOC DES PROD NESTLE SA
Anti-obesity agent comprising high-purity epa
ActiveUS20140155442A1Increase body weightLose weightBiocideMetabolism disorderFatty liverWeight gain prevention
The present invention provides an agent for preventing the increase in a body weight (or for decreasing a body weight) or an anti-obesity agent each comprising at least one component selected from the group consisting of EPA and pharmaceutically acceptable salts, esters and derivatives thereof as an active ingredient for obesity in which the increase in the formation of hepatic lipid or the occurrence of fatty liver is mild, preferably the increase in the formation of hepatic lipid or the occurrence of fatty liver is not observed.
Owner:AMARIN PHARMA IRELAND
Methods and treatment with glp-1 receptor agonists
InactiveUS20150111816A1Help control weightNot induce substantial nausea or appetite suppression in the patientConnective tissue peptidesPeptide/protein ingredientsDiabetes mellitusRegimen
The invention provides methods for treating diabetes or obesity, as well as methods for inducing weight loss, preventing weight gain, or controlling weight in a patient in need thereof. The methods comprise administering to the patient at least one effective dose of a GLP-1 receptor agonist, or a regimen of GLP-1 receptor agonist comprising a plurality of substantially evenly spaced doses. The effective dose or regimen does not induce substantial nausea or appetite suppression in the patient.
Owner:PHASEBIO PHARMA INC
Alpha-keto-isovalerate as a biomarker of prebiotic efficacy for weight gain prevention
InactiveUS9518975B2Lower Level RequirementsEfficient administrationOrganic active ingredientsMicrobiological testing/measurementPhysiologyNutrition
The present invention relates generally to the field of nutrition and health, particular, the present invention relates to alpha-keto-isovalerate as a biomarker urine of the efficacy of prebiotics for the prevention of diet induced weight gain.
Owner:SOC DES PROD NESTLE SA
Extracts of moricandia for the use thereof in the prevention and treatment of metabolic diseases
PendingUS20210346449A1Quickly reachAvoid weight gainMetabolism disorderFood scienceIGT - Impaired glucose tolerancePancreatic hormone
A composition including an extract of Moricandia for the use thereof in the prevention and/or treatment of metabolic diseases related to impaired glucose tolerance and/or insulin resistance. Also a composition including an extract of Moricandia for the use thereof in the prevention of weight gain, in particular of body fat.
Owner:UNIV DE BOURGOGNE (FR) +3
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Try Eureka
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap